SIRs of cancer among women with VTE during pregnancy and the postpartum period in Denmark, 1978-2013.
| Cancer cases . | All years . | Within 6 months after VTE . | Within 6-12 months after VTE . | >12 months after VTE . | ||||
|---|---|---|---|---|---|---|---|---|
| N . | SIR (95% CI) . | N . | SIR (95% CI) . | N . | SIR (95% CI) . | N . | SIR (95% CI) . | |
| All | 250 | 1.01 (0.89-1.14) | 4 | 1.77 (0.48-4.53) | 3 | 1.24 (0.26-3.63) | 243 | 1.00 (0.88-1.13) |
| VTE during pregnancy | 64 | 1.24 (0.96-1.59) | 0 | — | 3 | 3.27 (0.67-9.56) | 61 | 1.23 (0.94-1.58) |
| Deep venous thrombosis | 53 | 1.27 (0.95-1.66) | 0 | — | 3 | 4.15 (0.86-12.12) | 50 | 1.24 (0.92-1.63) |
| Superficial venous thrombosis | 11 | 1.14 (0.57-2.03) | 0 | — | 0 | — | 11 | 1.18 (0.59-2.11) |
| VTE in the postpartum period | 186 | 0.94 (0.91-1.09) | 4 | 2.86 (0.78-7.33) | 0 | — | 182 | 0.94 (0.81-1.08) |
| Deep venous thrombosis | 155 | 0.92 (0.78-1.08) | 4 | 3.84 (1.05-9.84) | 0 | — | 151 | 0.91 (0.77-1.06) |
| Superficial venous thrombosis | 31 | 1.09 (0.74-1.54) | 0 | — | 0 | — | 31 | 1.11 (0.76-1.58) |
| VTE location | ||||||||
| Deep and superficial thrombosis of the lower extremities | 215 | 1.01 (0.88-1.15) | 3 | 1.76 (0.36-5.15) | 1 | 0.55 (0.01-3.06) | 211 | 1.00 (0.87-1.15) |
| Pulmonary embolism | 18 | 0.91 (0.54-1.43) | 0 | — | 2 | 5.87 (0.71-21.19) | 16 | 0.83 (0.48-1.35) |
| Other sites | 17 | 1.14 (0.67-1.83) | 1 | 4.22 (0.11-23.49) | 0 | — | 16 | 1.11 (0.64-1.81) |
| Site-specific cancers | ||||||||
| Large intestine | 9 | 1.21 (0.56-2.30) | 1 | 29.65 (0.75-165.13) | 0 | — | 8 | 1.09 (0.47-2.14) |
| Lung, bronchi, and trachea | 10 | 0.72 (0.34-1.32) | 0 | — | 0 | — | 10 | 0.72 (0.34-1.32) |
| Malignant melanoma | 18 | 1.05 (0.62-1.66) | 0 | — | 0 | — | 18 | 1.10 (0.65-1.73) |
| Skin cancer (excluding basal cell carcinoma) | 4 | 0.80 (0.22-2.06) | 0 | — | 0 | — | 4 | 0.82 (0.22-2.09) |
| Other connective tissue | 3 | 2.33 (0.48-6.80) | 1 | 38.64 (0.98-215.20) | 0 | — | 2 | 1.62 (0.20-5.85) |
| Breast | 74 | 1.05 (0.82-1.32) | 0 | — | 1 | 2.15 (0.05-11.96) | 73 | 1.05 (0.82-1.32) |
| Cervix of uterus | 17 | 1.30 (0.76-2.08) | 0 | — | 1 | 2.78 (0.07-15.50) | 16 | 1.29 (0.74-2.10) |
| Uterus | 3 | 0.47 (0.10-1.36) | 0 | — | 0 | — | 3 | 0.47 (0.10-1.37) |
| Ovary | 4 | 0.55 (0.15-1.41) | 0 | — | 0 | — | 4 | 0.56 (0.15-1.44) |
| Brain | 4 | 0.66 (0.18-1.69) | 0 | — | 0 | — | 4 | 0.69 (0.19-1.77) |
| Spinal cord, cranial nerves, and central nervous system | 4 | 2.04 (0.56-5.23) | 1 | 33.45 (0.85-186.31) | 0 | — | 3 | 1.58 (0.33-4.62) |
| Thyroid gland | 3 | 0.84 (0.17-2.44) | 0 | — | 0 | — | 3 | 0.87 (0.18-2.55) |
| Non-Hodgkin malignant lymphoma | 7 | 1.29 (0.52-2.66) | 0 | — | 1 | 20.53 (0.52-114.37) | 6 | 1.13 (0.41-2.46) |
| Basal cell carcinoma | 63 | 1.14 (0.88-1.46) | 1 | 2.52 (0.06-14.06) | 0 | — | 62 | 1.14 (0.87-1.46) |
| Cancer cases . | All years . | Within 6 months after VTE . | Within 6-12 months after VTE . | >12 months after VTE . | ||||
|---|---|---|---|---|---|---|---|---|
| N . | SIR (95% CI) . | N . | SIR (95% CI) . | N . | SIR (95% CI) . | N . | SIR (95% CI) . | |
| All | 250 | 1.01 (0.89-1.14) | 4 | 1.77 (0.48-4.53) | 3 | 1.24 (0.26-3.63) | 243 | 1.00 (0.88-1.13) |
| VTE during pregnancy | 64 | 1.24 (0.96-1.59) | 0 | — | 3 | 3.27 (0.67-9.56) | 61 | 1.23 (0.94-1.58) |
| Deep venous thrombosis | 53 | 1.27 (0.95-1.66) | 0 | — | 3 | 4.15 (0.86-12.12) | 50 | 1.24 (0.92-1.63) |
| Superficial venous thrombosis | 11 | 1.14 (0.57-2.03) | 0 | — | 0 | — | 11 | 1.18 (0.59-2.11) |
| VTE in the postpartum period | 186 | 0.94 (0.91-1.09) | 4 | 2.86 (0.78-7.33) | 0 | — | 182 | 0.94 (0.81-1.08) |
| Deep venous thrombosis | 155 | 0.92 (0.78-1.08) | 4 | 3.84 (1.05-9.84) | 0 | — | 151 | 0.91 (0.77-1.06) |
| Superficial venous thrombosis | 31 | 1.09 (0.74-1.54) | 0 | — | 0 | — | 31 | 1.11 (0.76-1.58) |
| VTE location | ||||||||
| Deep and superficial thrombosis of the lower extremities | 215 | 1.01 (0.88-1.15) | 3 | 1.76 (0.36-5.15) | 1 | 0.55 (0.01-3.06) | 211 | 1.00 (0.87-1.15) |
| Pulmonary embolism | 18 | 0.91 (0.54-1.43) | 0 | — | 2 | 5.87 (0.71-21.19) | 16 | 0.83 (0.48-1.35) |
| Other sites | 17 | 1.14 (0.67-1.83) | 1 | 4.22 (0.11-23.49) | 0 | — | 16 | 1.11 (0.64-1.81) |
| Site-specific cancers | ||||||||
| Large intestine | 9 | 1.21 (0.56-2.30) | 1 | 29.65 (0.75-165.13) | 0 | — | 8 | 1.09 (0.47-2.14) |
| Lung, bronchi, and trachea | 10 | 0.72 (0.34-1.32) | 0 | — | 0 | — | 10 | 0.72 (0.34-1.32) |
| Malignant melanoma | 18 | 1.05 (0.62-1.66) | 0 | — | 0 | — | 18 | 1.10 (0.65-1.73) |
| Skin cancer (excluding basal cell carcinoma) | 4 | 0.80 (0.22-2.06) | 0 | — | 0 | — | 4 | 0.82 (0.22-2.09) |
| Other connective tissue | 3 | 2.33 (0.48-6.80) | 1 | 38.64 (0.98-215.20) | 0 | — | 2 | 1.62 (0.20-5.85) |
| Breast | 74 | 1.05 (0.82-1.32) | 0 | — | 1 | 2.15 (0.05-11.96) | 73 | 1.05 (0.82-1.32) |
| Cervix of uterus | 17 | 1.30 (0.76-2.08) | 0 | — | 1 | 2.78 (0.07-15.50) | 16 | 1.29 (0.74-2.10) |
| Uterus | 3 | 0.47 (0.10-1.36) | 0 | — | 0 | — | 3 | 0.47 (0.10-1.37) |
| Ovary | 4 | 0.55 (0.15-1.41) | 0 | — | 0 | — | 4 | 0.56 (0.15-1.44) |
| Brain | 4 | 0.66 (0.18-1.69) | 0 | — | 0 | — | 4 | 0.69 (0.19-1.77) |
| Spinal cord, cranial nerves, and central nervous system | 4 | 2.04 (0.56-5.23) | 1 | 33.45 (0.85-186.31) | 0 | — | 3 | 1.58 (0.33-4.62) |
| Thyroid gland | 3 | 0.84 (0.17-2.44) | 0 | — | 0 | — | 3 | 0.87 (0.18-2.55) |
| Non-Hodgkin malignant lymphoma | 7 | 1.29 (0.52-2.66) | 0 | — | 1 | 20.53 (0.52-114.37) | 6 | 1.13 (0.41-2.46) |
| Basal cell carcinoma | 63 | 1.14 (0.88-1.46) | 1 | 2.52 (0.06-14.06) | 0 | — | 62 | 1.14 (0.87-1.46) |
For site-specific cancers, only cancer types with ≥3 cases were included.